Compare Matson Inc (MATX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Matson Inc trades at $225.67 (market cap $6.81B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Matson Inc pays a 0.67% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MATX | XBI | |
|---|---|---|
Market Cap | $6.81B | $10.11B |
Volume | 255,080 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $238.60 | $169.55 |
52-Week Low | $88.05 | $104.99 |
Typical Hold Time | 23 Days | 38 Days |
Enterprise Value | $7.41B | — |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $225.67, up 1.23% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 12.7% and raising full-year guidance. Revenue growth continues with 2026 projections of $3.5B and net profit margins above 13%. Recent institutional buying from Bank of New York Mellon and Deutsche Bank highlights confidence in the shipping company's prospects.
MATX presents a compelling investment case with strong earnings momentum, reasonable valuation (P/E 15.37), and positive analyst sentiment (67% buy ratings). Key risks include freight market cyclicality and competitive pressures. The stock's 27.3% upside potential based on analyst targets and consistent dividend payments ($0.38 declared for H2-26) support a favorable outlook for value-oriented investors seeking transportation sector exposure.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
